These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

329 related items for PubMed ID: 19778861

  • 1. Molecular and genetic bases of myeloproliferative disorders: questions and perspectives.
    Plo I, Vainchenker W.
    Clin Lymphoma Myeloma; 2009; 9 Suppl 3():S329-39. PubMed ID: 19778861
    [Abstract] [Full Text] [Related]

  • 2. JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science.
    Kilpivaara O, Levine RL.
    Leukemia; 2008 Oct; 22(10):1813-7. PubMed ID: 18754026
    [Abstract] [Full Text] [Related]

  • 3. Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal.
    Vannucchi AM, Antonioli E, Guglielmelli P, Pardanani A, Tefferi A.
    Leukemia; 2008 Jul; 22(7):1299-307. PubMed ID: 18496562
    [Abstract] [Full Text] [Related]

  • 4. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
    Michiels JJ, Bernema Z, Van Bockstaele D, De Raeve H, Schroyens W.
    Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
    [Abstract] [Full Text] [Related]

  • 5. [Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases--principles and rationale of CZEMP recommendations].
    Schwarz J, Penka M, Campr V, Pospísilová D, Kren L, Nováková L, Bodzásová C, Brychtová Y, Cerná O, Dulícek P, Joniásová A, Kissová J, Korístek Z, Schützová M, Vonke I, Walterová L.
    Vnitr Lek; 2011 Feb; 57(2):189-213. PubMed ID: 21416861
    [Abstract] [Full Text] [Related]

  • 6. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.
    Zhan H, Spivak JL.
    Clin Adv Hematol Oncol; 2009 May; 7(5):334-42. PubMed ID: 19521323
    [Abstract] [Full Text] [Related]

  • 7. Histological and molecular classification of chronic myeloproliferative disorders in the age of JAK2: persistence of old questions despite new answers.
    Hussein K, Bock O, Kreipe H.
    Pathobiology; 2007 May; 74(2):72-80. PubMed ID: 17587878
    [Abstract] [Full Text] [Related]

  • 8. [Essential thrombocythemia. Contribution of the V617F JAK2 mutation to the pathophysiology, diagnosis and outcome].
    Brière J.
    Bull Acad Natl Med; 2007 Mar; 191(3):535-48. PubMed ID: 18072652
    [Abstract] [Full Text] [Related]

  • 9. [Myeloproliferative diseases caused by JAK2 mutation].
    Nagata K, Shimoda K.
    Rinsho Byori; 2009 Apr; 57(4):357-64. PubMed ID: 19489438
    [Abstract] [Full Text] [Related]

  • 10. Essential thrombocythemia, polycythemia vera, and myelofibrosis: current management and the prospect of targeted therapy.
    Tefferi A.
    Am J Hematol; 2008 Jun; 83(6):491-7. PubMed ID: 18429051
    [Abstract] [Full Text] [Related]

  • 11. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
    Rajnai H, Bödör C, Reiniger L, Timár B, Csernus B, Szepesi A, Csomor J, Matolcsy A.
    Orv Hetil; 2006 Nov 12; 147(45):2175-9. PubMed ID: 17402211
    [Abstract] [Full Text] [Related]

  • 12. Familial chronic myeloproliferative disorders: the state of the art.
    Rumi E.
    Hematol Oncol; 2008 Sep 12; 26(3):131-8. PubMed ID: 18484677
    [Abstract] [Full Text] [Related]

  • 13. [Detection and clinical significance of JAK2 mutation in 412 patients with chronic myeloproliferative neoplasms].
    Chao HY, Fan Z, Zhang R, Shen YM, Chen W, Fei HR, Zhu ZL, Feng YF, Chen ZX, Xue YQ.
    Zhonghua Zhong Liu Za Zhi; 2009 Jul 12; 31(7):510-4. PubMed ID: 19950698
    [Abstract] [Full Text] [Related]

  • 14. Advances in the molecular characterization of Philadelphia-negative chronic myeloproliferative disorders.
    Pikman Y, Levine RL.
    Curr Opin Oncol; 2007 Nov 12; 19(6):628-34. PubMed ID: 17906464
    [Abstract] [Full Text] [Related]

  • 15. [Research progress on molecular pathogenesis of myeloproliferative neoplasms].
    Liu L, Xiao ZJ.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Feb 12; 19(1):239-43. PubMed ID: 21362261
    [Abstract] [Full Text] [Related]

  • 16. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.
    Larsen TS, Pallisgaard N, Møller MB, Hasselbalch HC.
    Eur J Haematol; 2007 Dec 12; 79(6):508-15. PubMed ID: 17961178
    [Abstract] [Full Text] [Related]

  • 17. [Clinical significance of the quantification of JAK2V617F allele burden in classical Ph-negative myeloproliferative neoplasms].
    Kerguelén Fuentes AE, Hernández-Maraver D, Lombardia L, Canales Albendea MA, Rodriguez de la Rúa A.
    Med Clin (Barc); 2012 Oct 13; 139(9):373-8. PubMed ID: 22743278
    [Abstract] [Full Text] [Related]

  • 18. JAKing up hematopoietic proliferation.
    Shannon K, Van Etten RA.
    Cancer Cell; 2005 Apr 13; 7(4):291-3. PubMed ID: 15837617
    [Abstract] [Full Text] [Related]

  • 19. Molecular genetic evaluation of myeloproliferative neoplasms.
    Azzato EM, Bagg A.
    Int J Lab Hematol; 2015 May 13; 37 Suppl 1():61-71. PubMed ID: 25976962
    [Abstract] [Full Text] [Related]

  • 20. JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.
    Hussein K, Bock O, Theophile K, von Neuhoff N, Buhr T, Schlué J, Büsche G, Kreipe H.
    Exp Hematol; 2009 Oct 13; 37(10):1186-1193.e7. PubMed ID: 19616600
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.